Exact Sciences Corp gross margin has been in long-term decline. The average rate of decline per year is -2%.
The historical rank and industry rank for Exact Sciences's Gross Margin % or its related term are showing as below:
EXAS'
s Gross Margin % Range Over the Past 10 Years
Min: 37.88 Med: 70.53 Max: 76.24
Current: 69.55
During the past 13 years, the highestGross Margin % of Exact Sciences was 76.24%. The lowest was 37.88%. And the median was 70.53%.
EXAS's Gross Margin % is ranked better than 77.56% of 205
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.71
vs EXAS: 69.55
Exact Sciences had a gross margin of 60.16% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Exact Sciences was -2.00% per year.
Exact Sciences Gross Margin % Historical Data
The historical data trend for Exact Sciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's Gross Margin %
For the Diagnostics & Research subindustry, Exact Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's Gross Margin % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Exact Sciences had a gross margin of 60.16% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Exact Sciences Gross Margin % Related Terms
Thank you for viewing the detailed overview of Exact Sciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 